The present study revisited the three-dimensional (3D) homology model of CCK-2R using human A(2a) adenosine receptor and the resolved NMR based structure of the third extracellular loop of the CCK-2R as templates. Further in order to identify novel antiulcer agents, rational designing have been performed utilizing the substructure of a well-known CCK-2R antagonist benzotript as a lead molecule and submitted to the combined docking and simulation studies. This led to the understanding of the essential structure requirement as well as variation of binding mode among conformational isomers of small molecule CCK-2R antagonists. In the next step, preparation of each configurational isomer of these molecules was carried out and submitted for their in vitro activity followed by in vivo screening into antiulcer rat model. The biological screening of these compounds has not only validated the developed homology model of CCK-2R but also led to the identification of highly potent CCK-2R antagonist 6a as an orally active and safe candidate molecule having better antiulcer properties than the well-known drug benzotript.

10 Aug 2004·International Journal of CancerQ1 · MEDICINE

Glycine‐extended gastrin induces matrix metalloproteinase‐1‐ and ‐3‐mediated invasion of human colon cancer cells through type I collagen gel and Matrigel

Q1 · MEDICINE

Article

Author: Kazuyuki Itoh ; Masaharu Tatsuta ; Miyako Baba

AbstractThe effects of glycine‐extended gastrin (G‐Gly) on the invasion by colon cancer cells through stromal extracellular matrix and the role of metalloproteinases (MMPs) in this invasion were investigated. We found that 10−9–10−6 M G‐Gly significantly increased the invasiveness of 2 human colon cancer cell lines, LoVo and HT‐29, both expressing the G‐Gly‐specific binding site but little gastrin/CCK‐B receptor (gastrin receptor). LoVo cells expressed MMP‐1, ‐2, ‐3 and ‐9. An amount of 10−7 M G‐Gly enhanced collagenase MMP‐1 expression. Overexpression of enhanced green fluorescent protein (EGFP)‐fused MMP‐1 in LoVo cells, by cDNA transfection, enhanced invasiveness through type I collagen gel. Immunofluorescence study revealed that G‐Gly increased the number of cytoplasmic vesicles containing MMP‐1, some vesicles being released from the cells. The MMP‐1 vesicles contained one of the ubiquitous coat proteins, Golgi‐localized, γ‐adaptin ear‐containing, ARF‐binding proteins‐2 (GGA‐2). MMP‐1 also colocalized with CD147 (EMMPRIN, an extracellular matrix metalloproteinase inducer in adjacent stromal cells). It was suggested that G‐Gly increased the number of vesicles containing MMP‐1 and that MMP‐1 interacted with CD147 to increase invasion. G‐Gly significantly enhanced the production of MMP‐3, an activator of MMP‐1 and ‐9, as well as gelatinase MMP‐9 activity. The G‐Gly‐mediated MMP‐9 increase was inhibited by treatment with anti‐MMP‐3 IgG and MMP‐3 siRNA. Furthermore, G‐Gly increased the proMMP‐2 level, although no activated MMP‐2 was found in conditioned medium in either the presence or the absence of G‐Gly. By contrast, gastrin (10−7 M) had no effect on the levels of these MMPs or the invasiveness of colon cancer cells in type I collagen gel and Matrigel. These effects of G‐Gly on the activity and expression of MMPs and the invasiveness of colon cancer cells were inhibited by treating the cells with a broad‐spectrum metalloproteinase inhibitor (CGS27023A) and nonselective gastrin/CCK receptor antagonists (proglumide and benzotript). But a gastrin/CCK‐B receptor antagonist (YM022) did not inhibit the increased invasion by G‐Gly. Together, these results demonstrate that G‐Gly renders colon cancer cells more invasive by increasing MMP‐1 and MMP‐3 expressions via the putative G‐Gly receptor and would thus be a good molecular target in a clinical setting. © 2004 Wiley‐Liss, Inc.

01 Nov 2001·The International Journal of Biochemistry & Cell BiologyQ2 · BIOLOGY

Identification of a 70-kDa gastrin-binding protein on DLD-1 human colorectal carcinoma cells

Q2 · BIOLOGY

Article

Author: Chuan Hua Yang ; Arthur Shulkes ; Joanne Ford ; Shu Dong Xiao ; Yulia Karelina ; Graham S. Baldwin

Gastrin17gly acts as a growth factor for the colonic mucosa. Studies of the receptor involved have generally been restricted to its binding properties, and no investigation of the structure of gastrin17gly receptors on human colorectal carcinoma cell lines has yet been reported. The aim of this study was to optimise the conditions for binding of gastrin17gly to the human colorectal carcinoma cell line DLD-1, and to investigate the structure of the receptor responsible. Binding of 125I[Met15]gastrin17gly to DLD-1 cells was measured in competition experiments with increasing concentrations of either gastrin17gly or gastrin17, or with single concentrations of gastrin receptor antagonists. The molecular weights of the gastrin17gly binding proteins were determined by gel electrophoresis and autoradiography after covalent cross-linking of 125I[Nle15]gastrin2,17gly to cells or membranes with disuccinimidyl suberate. The IC50 value for binding of gastrin17gly to DLD-1 cells was 2.1+/-0.4 microM. Binding was inhibited by the non-selective gastrin/cholecystokinin receptor antagonists proglumide and benzotript, but not by the cholecystokinin-A receptor antagonist L364,718, or the gastrin/cholecystokinin-B receptor antagonist L365,260. The molecular weight of the major gastrin binding protein on DLD-1 cells or membranes was 70,000. We conclude that the major gastrin17gly binding site on the human colorectal carcinoma cell line DLD-1 is clearly distinct from the cholecystokinin-A and gastrin/cholecystokinin-B receptors, but is similar in some respects to the gastrin/cholecystokinin-C receptor.

100 Deals associated with Benzotript

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Ulcer	Phase 1	-	Rottapharm SpA	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Benzotript

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation